More MS news articles for September 2002

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12225898&dopt=Abstract

J Neuroimmunol 2002 Sep;130(1-2):163
Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Astrom M, Hedlund G.
Active Biotech Research AB, Box 724, S-220 07, Lund, Sweden

A new orally active drug, laquinimod (ABR-215062), was shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE).

Furthermore, leukocyte infiltration into the central nervous system (CNS) was abolished in the laquinimod-treated animals.

By direct comparison based on dose and total exposure, laquinimod was approximately 20 times more potent than the immunomodulator roquinimex.

Laquinimod also had clear therapeutic effect when given after clinical onset in a chronic relapsing EAE model.

It therefore represents a new orally active immunoregulatory drug without general immunosuppressive properties for the treatment of the autoimmune disease multiple sclerosis.